SOLICITATION NOTICE
B -- Services to Provide Estimates of the Risk of Progressing to Recurrence Under Competing Risk Framework.
- Notice Date
- 8/30/2018
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02PC82637-61
- Archive Date
- 9/20/2018
- Point of Contact
- KATHY D. ELLIOTT, Phone: 240-276-5570, Jolomi Omatete, Phone: 2402766561
- E-Mail Address
-
ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov
(ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Description The National Cancer Institute (NCI), Division of Cancer Control & Population Sciences (DCCPS), Data Analytics Branch (DAB), Surveillance Research Program (SRP) plans to procure, on a sole source basis, services to provide estimates of the risk of progressing to recurrence under competing risk framework from Fondazione IRCCS Istituto Nazionale Dei Tumori, Campus Cascina Rosa, Via Vanzetti 5, Milano, Italy 20133. The response close date of this notice is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1 (b)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System (NAICS) code is 541990 and the business size standard is $15 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance shall be 12 months from the date of award. It has been determined that there is no opportunity to acquire green products or services under this contract. The Surveillance Research Program (SRP) supports a program of research on the science of cancer surveillance as well as analytical tools and methodological expertise in collecting, analyzing, interpreting, and disseminating reliable population-based cancer statistics. One of SRP priorities is on developing approaches and methods for the collections and quantification of cancer recurrence. Distant metastatic recurrence is a key outcome in the management of disease at both the individual and the population levels. Recurrence is the return of cancer after primary treatment and reflects progression to a greater disease burden. Population-representative risks of metastatic recurrence are not available in the US since cancer registries do not collect data on recurrence. Recently, a novel method has been developed that estimates the risk of recurrence using cancer registry disease-specific survival combined with data from external cohorts that contain information on the survival after a cancer recurrence. The method is a generalization of Gatta et al (2004) (1) and is based on an illness-death process coupled with a mixture-cure model for net cancer survival. The risk of recurrence is inferred from the estimated survival among the non-cured fraction and published data on survival after recurrence. The method also uses a convolution method based on prior work from Capocaccia et al (1993)(2). The above method provides population-based information on the proportion who recurred and the distribution of recurrence times and holds potential for expanding cancer registry reports to provide a more complete picture of the burden of disease and progress on cancer control. Because the methods rely on net cancer survival measures (cause-specific or relative survival), the estimates represent summaries of the risk of metastatic recurrence in the absence of other causes of death; i.e., in the hypothetical world that cancer patients cannot die of other causes. This is far less useful than measures that incorporate the risks of dying of other causes. The Contractor shall develop the methods, equations and formulas to be used for the calculation of four (4) measures by time since diagnosis and including risks of dying of competing causes: a) Alive and cured; b) Alive, not cured, and not in recurrence; c) Alive, not cured, and in recurrence; and d) Died (cancer cause or competing cause) The Contractor shall apply the methods to colon cancer data to estimate the crude risks of a) alive and cured, b) alive, not cured, and not in recurrence, c) alive, not cured, and in recurrence, and d) died in a competing risk framework. The Contractor shall perform the following tasks: 1. Develop methodology and algorithm to derive the crude probabilities of a) alive and cured, b) alive not cure and not in recurrence, c) alive not cured and in recurrence, and d) died in a competing risk framework. The method should take into consideration life tables by comorbidity and how the mixture cure survival models are used in a competing risk framework. 2. Apply the methods using colon cancer cases to estimate the probabilities of being a) alive and cured, b) alive not cure and not in recurrence, c) alive not cured and in recurrence, and d) dead x years from diagnosis in a competing risk framework. Send two (2) researchers from Italy for a two-day in-person progress meeting at the NCI offices in Rockville, MD to present the methods to NCI statisticians, to fine tune the methods, and to interpret preliminary results from the application to patients diagnosed with colon cancer using the SEER data. The date will be determined after date of award. Report(s)/deliverables and delivery schedule: Deliverables shall be sent to the NCI COR via e-mail in Microsoft compatible format. 1. The Contractor shall provide a short report summarizing the methodology and algorithm. DUE DATE: 6 months from date of award 2. The Contractor shall provide a short report with a table and with the estimates by annual years since diagnosis from 1 to 15 years. DUE DATE: 12 months from date of award Place of Performance: The place of performance shall be at the Contractor's facility. Payment: Payment shall be made upon acceptance and approval of deliverable. Payment authorization requires monthly submission and approval of invoices to the COR and NIH OFM. The NCI requires the Contractor to develop the methods and measures required to the calculation crude probabilities of the different phases of disease in a competing risk framework The NCI COR reviewed literature in various publications and are abreast of subject matter experts in this field The Istituto Nazionale dei Tumori's previous work on estimating the differing care needs of colon cancer patients is the foundation for the work in this acquisition. The Istituto Nazionale dei Tumori has the expertise and tools to develop the methods and measures required to the calculation crude probabilities of the different phases of disease in a competing risk framework. In addition, this is the only known entity in the world that presently has the depth of knowledge and expertise in the area of surveillance and cancer statistics for rare cancers that are known to the NCI. This is not a solicitation for competitive quotations. However, if any interested parties, especially small businesses, believe they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. A copy of the capability statement must be received in the NCI Office of Acquisition on or before 11:00AM EST on August 29, 2018. All questions must be in writing and can be faxed (240) 276-5401 or emailed to Kathy Elliott, Contract Specialist at Elliottk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification on Sam.gov, www.sam.gov. No collect calls will be accepted. Please reference solicitation number N02RC82637-61 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02PC82637-61/listing.html)
- Place of Performance
- Address: 9609 Medical Center Drive, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN05063761-W 20180901/180830231150-999a7f91cd78a36adad3396b6a5d44d2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |